(Condition-5): the particle size distribution of the lactose hydrate measured by particle size analysis-laser diffraction methods has

a 10% by weight particle size of 19 μm to 43 μm,

a 50% by weight particle size of 53 μm to 66 μm, and

a 90% by weight particle size of 75 μm to 106 μm,

and the lactose hydrate satisfying (Condition-3) further satisfies

(Condition-8): the particle size distribution of the lactose hydrate measured by particle size analysis-laser diffraction methods has

a 10% by weight particle size of 1 μm to 3 μm,

a 50% by weight particle size of 11 μm to 20 μm, and

a 90% by weight particle size of 37 μm to 54 μm.

~~11. The dry powder pharmaceutical composition for inhalation according to claim 7, wherein the diluting agent comprises a lactose hydrate satisfying (Condition-2) and a lactose hydrate satisfying (Condition-8), and the weight ratio between the lactose hydrate satisfying (Condition-2) and the lactose hydrate satisfying (Condition-8) is from 50:50 to 100:0.~~

~~12. The dry powder pharmaceutical composition for inhalation according to claim 8, wherein the diluting agent comprises a lactose hydrate satisfying (Condition-2) and a lactose hydrate satisfying (Condition-4), and the weight ratio between the lactose hydrate satisfying (Condition-2) and the lactose hydrate satisfying (Condition-4) is from 50:50 to 100:0.~~

~~13. The dry powder pharmaceutical composition for inhalation~~

~~according to claim 9, wherein the diluting agent comprises a lactose hydrate satisfying (Condition-5) and a lactose hydrate satisfying (Condition-4), and the weight ratio between the lactose hydrate satisfying (Condition-5) and the lactose hydrate satisfying (Condition-4) is from 50:50 to 100:0.~~

~~14. The dry powder pharmaceutical composition for inhalation according to claim 10, wherein the diluting agent comprises a lactose hydrate satisfying (Condition-5) and a lactose hydrate satisfying (Condition-8), and the weight ratio between the lactose hydrate satisfying (Condition-5) and the lactose hydrate satisfying (Condition-8) is from 50:50 to 100:0.~~

~~15. The dry powder pharmaceutical composition for inhalation according to claim 7 or 11, wherein the diluting agent comprises a lactose hydrate satisfying (Condition-2) and a lactose hydrate satisfying (Condition-8), and the lactose hydrate satisfying (Condition-2) has a particle size controlled by sieving, and the lactose hydrate satisfying (Condition-8) has a particle size controlled by pulverization.~~

~~16. The dry powder pharmaceutical composition for inhalation according to claim 8 or 12, wherein the diluting agent comprises a lactose hydrate satisfying (Condition-2) and a lactose hydrate satisfying (Condition-4), the lactose hydrate satisfying (Condition-2) has a particle size controlled by sieving, and the lactose hydrate satisfying (Condition-4) has a particle size controlled by pulverization.~~

~~17. The dry powder pharmaceutical composition for inhalation according to claim 9 or 13, wherein the diluting agent comprises~~

~~a lactose hydrate satisfying (Condition-5) and a lactose hydrate satisfying (Condition-4), the lactose hydrate satisfying (Condition-5) has a particle size controlled by sieving, and the lactose hydrate satisfying (Condition-4) has a particle size controlled by pulverization.~~

~~18. The dry powder pharmaceutical composition for inhalation according to claim 10 or 14, wherein the diluting agent comprises a lactose hydrate satisfying (Condition-5) and a lactose hydrate satisfying (Condition-8), the lactose hydrate satisfying (Condition-5) has a particle size controlled by sieving, and the lactose hydrate satisfying (Condition-8) has a particle size controlled by pulverization.~~

11~~19~~. The dry powder pharmaceutical composition for inhalation according to any one of claims 1 to 10~~18~~, wherein the medicinal component has a 50% by weight particle size of 3.2 μm or less and a 90% by weight particle size of 8.0 μm or less as measured by particle size analysis-laser diffraction methods.

12~~20~~. The dry powder pharmaceutical composition for inhalation according to any one of claims 1 to 11~~19~~, comprising 4% by weight to 30% by weight, on an anhydrous basis, of the medicinal component.

13~~21~~. The dry powder pharmaceutical composition for inhalation according to any one of claims 1 to 11~~19~~, comprising 15% by weight to 25% by weight, on an anhydrous basis, of the medicinal component.

14~~22~~. The dry powder pharmaceutical composition for inhalation according to any one of claims 1 to 11~~19~~, comprising 20% by weight,

on an anhydrous basis, of the medicinal component.

15~~23~~. The use of a dry powder pharmaceutical composition for inhalation according to any one of claims 1 to 14~~22~~ in the manufacture of a medicament for preventing influenza by inhalation to a respiratory system of a human subject before onset of an influenza virus infection, wherein the dose of the medicinal component to be administered is from 5 to 120 mg on an anhydrous basis.

16~~24~~. The use of a dry powder pharmaceutical composition for inhalation according to any one of claims 1 to 14~~22~~ in the manufacture of a medicament for treating influenza by inhalation to a respiratory system of a human subject in onset of an influenza virus infection, wherein the dose of the medicinal component to be administered is from 5 to 120 mg on an anhydrous basis, and the dose is to be used as a single dose or in two divided doses.

17~~25~~. The use according to claim 15~~23~~ or 16~~24~~, wherein the dose of the medicinal component is 20 mg on an anhydrous basis, which is to be administered in a single inhaled dose.

18~~26~~. The use according to claim 16~~24~~, wherein the dose of the medicinal component is 20 mg on an anhydrous basis, which is to be administered in two inhaled doses.

19~~27~~. The use according to claim 15~~23~~ or 16~~24~~, wherein the dose of the medicinal component is 40 mg on an anhydrous basis, which is to be administered in a single inhaled dose.

20~~28~~. The use according to claim 15~~23~~ or 16~~24~~, wherein the dose of the medicinal component is 80 mg on an anhydrous basis, which

is to be administered in a single inhaled dose.